We would love to hear your thoughts about our site and services, please take our survey here.
Why GSK has created a cross-functional team to ‘future-proof’ its brands
GSK Consumer Healthcare’s CMO Tamara Rodgers believes there are “too many” siloes within organisations today, as she works on building collaborative and agile teams.
https://www.marketingweek.com/gsk-cross-functional-team/
denby
Both Merck and Pfizer Antiviral pills increase the rate of cancer by 75% , both are carcinogenic.
In Trials, they reported raised liver enzymes and anemia .. Covid 19. Its one of 100's of variations.
Maybe look deeper and see that all current vaccines do not address anything else.. Vir Monoclonal antibody does, it can treat all corona viruses not just number 19 .. No vaccine even did the basics..
Read and it will help, but all vaccine transmit the virus, and to people with medical conditions like Hepatic disease
Sotrovimab was developed
https://www.nature.com/articles/s41586-021-03807-6
USA/Brazil/UAE/EU/Canada/Australia/Singapore
THE LIST IS ENDLESS , UK only appproved when Omicrom came along.,as they knew the vaccines are hopeles
https://www.europeanpharmaceuticalreview.com/news/166041/mhra-approves-xevudy-sotrovimab-to-treat-covid-19/
UAE announces two-week treatment results for Covid-19 medicine Sotrovimab
Led to 100 per cent prevention of death and 99 per cent prevention of admissions to ICU
Between 30 June and 13 July, Sotrovimab was administered to 6,175 patients with Covid-19 in Abu Dhabi. About 52 per cent of the patients were aged 50 or above, and almost all recipients had multiple comorbidities including obesity, cancer, cardiovascular disease and diabetes.
97 per cent of recipients fully recovered within 14 days. The medication also resulted in 100 per cent prevention of death among recipients and 99 per cent prevention of admission to ICU.
https://www.mediaoffice.abudhabi/en/health/uae-announces-2-week-treatment-results-for-covid19-medicine-sotrovimab/
GSK was more optimistic about its mAb with Vir, which the companies said was “deliberately designed with a mutating virus in mind.” A GSK spokesperson told Endpoints News via email: “Based on the sequence of the Omicron variant, we believe sotrovimab is likely to maintain activity and potency against this variant
https://endpts.com/first-case-of-omicron-in-the-us-adds-to-pressure-of-figuring-out-which-mabs-or-vaccines-might-not-work-as-well/
The supply of Sotrovimab is delivered in full By December 17... Its also the only Antibody worldwide that works on Delta, Delta Plus, Lambda and MU, no other antibody works and the antivirals do not even work on alpha or Delta... GSK-VIR dose not supply silly pills like Pfizer or Merk and it mAbs are not able to be matched by any company..
LONDON and SAN FRANCISCO, Nov. 17, 2021 (GLOBE NEWSWIRE) -- GlaxoSmithKline plc (LSE/NYSE: GSK) and Vir Biotechnology, Inc. (Nasdaq: VIR) today announced US government contracts totaling approximately $1 billion1 (USD) to purchase sotrovimab, an investigational monoclonal antibody for the early treatment of COVID-19, which the US Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) in May 2021. GSK will supply these doses to the US government by December 17, 2021, enabling further expanded nationwide access to sotrovimab for patients.
https://www.globenewswire.com/news-release/2021/11/17/2336173/0/en/GSK-and-Vir-Biotechnology-Announce-United-States-Government-Agreements-to-Purchase-Sotrovimab-a-COVID-19-Treatment.html
Watch and learn what GSK as , that no other pharma as been able to do
https://www.cnbc.com/video/2021/11/17/vir-biotechnology-president-ceo-explores-companys-1b-u-s-government-deal.html
Already passed , and accounted for.. $643.4 million
From The Center Square
A Florida Legislature panel authorized to make between-session budget decisions Thursday approved a $1.2 billion supplemental funding request by the state’s Division of Emergency Management (DEM) to respond to the COVID-19 pandemic.
The 14-member Joint Legislative Budget Commission unanimously approved the DEM’s request, which will fund three initiatives from federal pandemic and stimulus allocations already received by the state or eligible for future federal reimbursement.
The largest single expenditure in the $1.2 billion supplemental funding request is $643.4 million to acquire about 300,000 doses – at $2,100 each – of GlaxoSmithKline’s sotrovimab, a relatively new monoclonal antibody treatment not yet directly available through federal supply lines.
DEM Financial Management Administrator Mark Mahoney said the request for sotrovimab is more of a precaution than an urgency because the COVID-19 pandemic appears to be on a sustained wane in Florida and across the country.
“We’re seeing a sharp decline right now in cases, so it doesn’t seem to be basically as much of a need,” Mahoney told the committee. “However, this authority should give us enough headroom should there be another spike, should we need to increase the antivirals and use something besides Regeneron.”
The funding request was sponsored by Gov. Ron DeSantis, who wants the state to acquire its sotrovimab as a precaution after Florida was, he said, purposely shorted for political reasons by the Biden administration when it rationed supplies of Regeneron’s REGN-COV2 monoclonal antibody treatments.
Monoclonal antibody treatments are an increasingly popular alternative to vaccines for protection from COVID-19. So popular that in September, the U.S. Department of Health & Human Services (DHS), increased overall supplies by 50%, from 100,000 to 150,000 doses a week nationwide, but capped doses being delivered to Florida and six other Southern states that had previously consumed more than 70% of the nation’s monoclonal antibody treatments.
According to the Governor’s Office, state clinics and private providers had been ordering about 72,000 monoclonal antibody treatments, or doses, a week.
That place has dramatically declined as case counts have dropped. The Department of Health (DOH) projects it will administer 26,000 doses a week across the state’s 25 treatment sites through year’s end. DeSantis met with GSK leadership to discuss the latest of federally-approved monoclonal antibody therapies, sotrovimab.
“We’re going to be able to use that sotrovimab to bridge some of the gaps that are going to be developing as a result of the Biden administration dramatically cutting medications to the state of Florida,” he said.
The state spent $6.51 million to purchase 3,100 sotrovimab doses in September even though, despite the dose cap, the feared shortage of Regeneron REGN-COV2 never materiali
Florida state bypasses Biden Administration again for GlaxoSmithKline’s sotrovimab
https://www.theapopkavoice.com/stories/florida-panel-okays-643-million-precautionary-stash-of-monoclonal-antibody-treatments,11821
Dunnieboy
Item 8.01
Other Events.
Update on Global Access to Sotrovimab for COVID-19 Patients
Vir Biotechnology, Inc. (the “Company”) today announced significant progress increasing global patient access to sotrovimab, an investigational monoclonal antibody treatment for COVID-19 developed in partnership with GlaxoSmithKline. To date, binding agreements have been received for the sale of more than 420,000 doses of sotrovimab worldwide, including a portion of those procured by the U.S. government. In addition, more than 220,000 doses have been reserved through other agreements. The companies continue discussions with governments around the world for additional agreements that can support the ongoing pandemic response.
Dunnieboy, I dont post much on here, as the kids play to much .
VIR7831 7832 Sotrovimab is used in Australia, Canada France , Italy, Abbu Dhabi, United Arab Emeriates, Brazil, USA, Florida having a separate contract of 30,000 doses it procured .Saudi Arabia, Singapore , the EU as 220,000 dose contract, now the UK wants to buy it..
Time will tell, but todate, Merck Pill as 50% effectiveness, Astra synthetic antiviiral as the same, Eli Lilly MAbs as been withdrawn in 13 US states, and Regeneron is only at 70% , suspect the world is waking up to VIR GSK Monoclonal Antibody, and it as shown 99% Effectiveness in UAE, and 99% Effectiveness in Australia ... If the UK goes down the route of 100,000 it just re inforces how poor the current prevention of Covid 19 is doing in the UK,
Contrary to the belief of the kids, Vir is the most prized asset GSK have its worth more than the Consumer health side in the long term
I have never been banned, where were u hiding at the $16 .00 of CVAC, where were you hiding at VIR $12. 00.
Funny that, as both are 4 x higher thanh what you say, but then you are thenLSE ponzi scammer
You are one thick idiotic clown who as an agenda and thinks they know something.
michnaz
GSK VIR monoclonal antibody is used world wide now, the UK as not approved it due to them being stuck up Astra Backside.
Its unique and no other monoclonal antibody as such high rates of success. With case numbers increasing world wide of new variants that current vaccines do not work on, other world nations are ramping up its use and its now being considered in the UAE as better than the vaccines
The cost of an ICU bed in the uk per day is $80,000 per day.
The cost of having a bed in the uk and staff to use the IV for the monoclnal antibody is £1400 and it saves lives, todate its saved over 45000 lives, but the UK lives are expendable ..
Japan administred 600 people Sotrovimab with in the first day
Sotrovimab, was developed by GlaxoSmithKline and Vir Biotechnology after a large collaborative study by scientists found a natural antibody in the blood of a SARS survivor, back in 2003 that has a remarkable breadth and efficacy.
This will really show up the vaccine fall out, its now being ramped up in production due to every vaccine fall out and failure to save lives.. Of Course its a UK Company, but one that the UK Government as not backed or MHRA approved but its approved world wide, so 700 Brits died last week from Covid 99% could have been saved.......
https://scitechdaily.com/inescapable-covid-19-antibody-discovery-neutralizes-all-known-sars-cov-2-strains/#google_vignette
https://www.healio.com/news/rheumatology/20210817/calabrese-to-rheumatologists-on-covid19-breakthrough-cases-those-are-our-patients
Ignore the usual suspect .. Again this is MABs use in the USA rose 300% last week
Dunnie.
Slide 9 https://investors.vir.bio/static-files/08bc6665-d0a9-4e86-b746-35ad88fa0235
Suspect the UK are dragging there heels on saving UK lives-why all other countries are using it
Is GSK A UK company or is it Russian, wonder why the UK lest people die , when they can save lives with it..
Paupucsilly.
If a share price rises on good news , it means the company have something and build on it.
You keep up all your efforts, you wasting your time being here, and have proven that time and time again